COMPARISON OF FEV1 REGARDLESS OF RATIO (FRR) WITH FORCED EXPIRATORY RATIO (FER) IN COPD; TO INCORPORATE PRESERVED RATIO IMPAIRED SPIROMETRY (PRISM)

Similar documents
Supplementary Online Content

Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?

This is a cross-sectional analysis of the National Health and Nutrition Examination

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation

What do pulmonary function tests tell you?

Basic approach to PFT interpretation. Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic

Assessment of Pulmonary Artery Pressure in Chronic Obstructive Pulmonary Disease Patients without Resting Hypoxemia

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

9/22/2015 CONFLICT OF INTEREST OBJECTIVES. Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR

Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR

Decramer 2014 a &b [21]

Guideline for the Diagnosis and Management of COPD

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life

Difference Between The Slow Vital Capacity And Forced Vital Capacity: Predictor Of Hyperinflation In Patients With Airflow Obstruction

COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases

Online Data Supplement. Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey

Combined Pulmonary Fibrosis and Emphysema - A Case Series

Asthma COPD Overlap (ACO)

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

Triennial Pulmonary Workshop 2012

Prevalence of undetected persistent airflow obstruction in male smokers years old

Bode index as a predictor of severity in patients with chronic obstructive pulmonary disease.

To assess the pulmonary impairment in treated pulmonary tuberculosis patients using spirometry

Yuriy Feschenko, Liudmyla Iashyna, Ksenia Nazarenko and Svitlana Opimakh

DIAGNOSTIC NOTE TEMPLATE

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

COPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS

Pulmonary Function Testing

The role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE

Anyone who smokes and/or has shortness of breath and sputum production could have COPD

Spirometry is the most frequently performed. Obstructive and restrictive spirometric patterns: fixed cut-offs for FEV1/FEV6 and FEV6

The Aging Lung. Sidney S. Braman MD FACP FCCP Professor of Medicine Brown University Providence RI

Question by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD)

REQUISITION FOR DIAGNOSTIC SERVICES

COPD. Breathing Made Easier

COPD: Current Medical Therapy

PDF of Trial CTRI Website URL -

COPD in Korea. Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

6- Lung Volumes and Pulmonary Function Tests

Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions?

S P I R O M E T R Y. Objectives. Objectives 3/12/2018

Coexistence of confirmed obstruction in spirometry and restriction in body plethysmography, e.g.: COPD + pulmonary fibrosis

Supplementary Appendix

OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:

Spirometry: an essential clinical measurement

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Referring for specialist respiratory input. Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL

Assessment of Airflow Obstruction in Post-Tubercular COPD Patients And non-tubercular COPD Patients: A Comperative Study

Teacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology

Correlation of the Ratio of Upper Third to Lower Third Circumferences of the Chest with Obstructive Pattern in Spirometry

Chronic obstructive pulmonary disease in over 16s: diagnosis and management

Supplementary Online Content

Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects

Pulmonary Function Testing The Basics of Interpretation

COMPARISON BETWEEN INTERCOSTAL STRETCH AND BREATHING CONTROL ON PULMONARY FUNCTION PARAMETER IN SMOKING ADULTHOOD: A PILOT STUDY

APSR RESPIRATORY UPDATES

Comparison between FEV1/FEV6 and FEV1/FVC as screening of chronic obstructive pulmonary disease

Course Handouts & Disclosure

Chapter. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

Gender Differences in the Severity of CT Emphysema in COPD*

Pulmonary Function Testing

Implications of the pulmonary artery to ascending aortic ratio in patients with relatively mild chronic obstructive pulmonary disease

Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD?

Preoperative assessment for lung resection. RA Dyer

Page 126. Type of Publication: Original Research Paper. Corresponding Author: Dr. Rajesh V., Volume 3 Issue - 4, Page No

Differential diagnosis

Understanding the Basics of Spirometry It s not just about yelling blow

RESPIRATORY PHYSIOLOGY Pre-Lab Guide

PFT Interpretation and Reference Values

Lab 4: Respiratory Physiology and Pathophysiology

HEART and LUNG. Heart failure and COPD Χ. ΑΔΑΜΟΠΟΥΛΟΣ ΓΝΘ «ΑΓΙΟΣ ΠΑΥΛΟΣ»

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

Predictive Models of Emphysema Progression in HIV

Chronic Obstructive Pulmonary Disease (COPD) Copyright 2014 by Mosby, an imprint of Elsevier Inc.

Parametric response mapping

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

PULMONARY FUNCTION TESTING. Purposes of Pulmonary Tests. General Categories of Lung Diseases. Types of PF Tests

Comparison between Spirometry and BODE Index for Clinical Assessment in Chronic Obstructive Pulmonary Disease Patients

Relevant Papers: eight relevant articles were found, but four were reviewed because they were most directly related to the topic

Respiratory Disease. Dr Amal Damrah consultant Neonatologist and Paediatrician

PULMONARY FUNCTION. VOLUMES AND CAPACITIES

Respiratory Function Testing Is Safe in Patients With Abdominal Aortic Aneurysms.

Lecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease

Interpreting pulmonary function tests: Recognize the pattern, and the diagnosis will follow

Office Based Spirometry

COPD Diagnosis, Management and Program

Cigarette Smoking and Lung Obstruction Among Adults Aged 40 79: United States,

Over the last several years various national and

S P I R O M E T R Y. Objectives. Objectives 2/5/2019

PULMONARY FUNCTION TESTS

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation

Transcription:

wjpmr, 2017,3(9), 03-07 SJIF Impact Factor: 4.103 WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH Research Article ISSN 2455-3301 WJPMR COMPARISON OF FEV1 REGARDLESS OF RATIO (FRR) WITH FORCED EXPIRATORY RATIO (FER) IN COPD; TO INCORPORATE PRESERVED RATIO IMPAIRED SPIROMETRY (PRISM) Dr. Kanwal Fatima Khalil* MCPS (MED). MRCP (UK) FCPS (Pulmonology) Consultant & Head, Department of Pulmonology Assistant Professor, Fauji Foundation Hospital Rawalpindi. *Corresponding Author: Dr. Kanwal Fatima Khalil MCPS (MED). MRCP (UK) FCPS (Pulmonology) Consultant & Head, Department of Pulmonology Assistant Professor, Fauji Foundation Hospital Rawalpindi. Article Received on 26/07/2017 Article Revised on 15/08/2017 Article Accepted on 05/08/2017 ABSTRACT Background: Traditionally spirometric criteria of post-bronchodilator FEV1/FVC is used to define Chronic Obstructive Pulmonary Disease(COPD). This has been termed as forced expiratory ratio(fer)(1). It is however, well observed that people who smoke even if do not fulfill the GOLD definition, still continue to experience symptoms and behave in a similar manner. This indicates that the current criteria of diagnosis of COPD may not be sufficient in all cases. Objective: To compare the validity of FEV1 regardless of ratio (FRR) with GOLD defined COPD (Forced expiratory ratio FER) and to identify patients with PRISM as a separate group. Methods: It was an analytical type of study undertaken in the Department of Pulmonology, Fauji Foundation Hospital Rawalpindi on 123 stable patients, who presented to the outpatient department (OPD) for evaluation of their symptoms, from July 2015 to August 2017. Data was analyzed by calculating frequencies and percentages using SPSS version 20. Validity of FER, FRR was calculated by checking the sensitivity, specificity, positive and negative predictive values. PRISM was identified as a subgroup. Results: The mean age of patients was 63.41 +10.28. Around 108(87.80%) of patients were male while 15(12.20%) were female. GOLD Defined COPD group and the PRISM groups were comparable with no statistically significant difference in their mean age, smoking status, arterial blood gas values and the six minute walk test. The sensitivity and specificity of GOLD defined COPD is modest (53.50% and 45.50%) and FEV1 regardless of ratio(frr) has got an improved sensitivity (98.2%) and positive predictive value (91.66%). Discussion: The sensitivity of FRR in the present study was more than 90% ; implicating its use in mass screening programs for COPD, in the communities and multiple health care centers of the world. Conclusion: Using FEV1 regardless of ratio (FRR) is a an easy and widely available parameter that can be useful in future hence reducing the morbidity and mortality that can be a consequence of missing a diagnosis. KEY WORDS: Chronic Obstructive Lung Disease, Spirometry, Standards, Forced Expiratory Volume, Validity of Results. INTRODUCTION Chronic Obstructive Pulmonary Disease(COPD) is one of the leading cause of deaths throughout the world. [2] It has an overall prevalence of 10%-12%. [1,3] Cigarette smoking is one of the main risk factor for this illness. [4] It is linked with progressive decline in FEV1 with age(5). FEV1 is influenced by reduced elastic recoil of lungs along with alveolar wall destruction. Studies have demonstrated small airway disease in smokers who do not have overt signs of COPD or reduction in FEV1. [5] Spirometry is the most simple, readily available tool for screening purposes. [2] The definition of COPD is quite complex. Traditionally spirometric criteria of postbronchodilator FEV1/FVC <70% is used to define this illness. This has been termed as forced expiratory ratio(fer). [1] It is however, well observed that people who smoke even if do not fulfill the GOLD definition, still continue to experience symptoms and behave in a similar manner. This indicates that the current criteria of diagnosis of COPD may not be sufficient in all cases. [4] Spirometry pattern of FEV1/FVC ratio more than 70% but an FEV1 < 80% is given as a restrictive defect by Global Initiative of Obstructive Lung Disease (GOLD) registry, but numerous studies have demonstrate that smokers who exhibit this feature have evidence of increase in total lung capacity(tlc) as measured by total body plethysmography or CT scan. [5] Preserved ratio impaired spirometry (PRISM) is the term used to describe these patients. [6] Both FEV1 and FVC progressively decline with age, but studies have shown that decline of FEV1 is more rapid and consistent with age and smoking status. [2] Using FEV1 regardless of 3

ratio(frr) as a diagnostic criteria may lead to GOLD COPD stage I(FEV1/FVC <70%, FEV1> 80%) to be missed; however, it has been described that patients usually report symptoms when they are in stage II(FEV1< 80%>50%) and stage III(FEV1 >30% <50%), when it is likely to be picked up by FRR. Conversely FEV1 is found to be reduced in many smokers with normal FEV1/FVC ratio. These patients though classified as having restrictive defect behave in a manner similar to GOLD defined COPD patients. [7] Many alternate criteria had been developed to incorporate these patients with restrictive defect ; including FEV1/FEV6 [8] and the famous 5 th percentile criteria proposed by American Thoracic Society. [9] These criteria, however, complicate the diagnosis of COPD. To remain simple, FEV1 as a criteria for diagnosis of COPD is reliable and more predictive of decline in lung function. [2] The main benefit of FEV1 regardless of ratio(frr) is to incorporate patients missed by FER. This subgroup, termed as GOLD unclassified smokers is now recognized as a separate identity known as preserved ratio impaired Spirometry (PRISM). In the famous COPDGene Study, the prevalence of PRISM in population was 12.3%. [6] The objective of this study was to compare the validity of FEV1 regardless of ratio (FRR) with GOLD defined COPD (Forced expiratory ratio FER) and to identify patients with PRISM as a separate group. MATERIAL AND METHODS It was an analytical type of study undertaken in the Department of Pulmonology, Fauji Foundation Hospital Rawalpindi on 123 stable patients, who presented to the outpatient department (OPD) for evaluation of their symptoms. The study duration was 2 years from July 2015 to July 2017. Sample size was calculated by WHO sample size calculator as 120. According to a study by Johns and colleagues, 80% of patients with COPD are diagnosed by spirometry using FER criteria. [1] Using the sensitivity calculator and an absolute precision of 0.08, sample size was 120. Hence 123 patients were included in the study. GOLD defined COPD, also named Forced expiratory ratio (FER) was defined on Spirometry as given by Global Initiative of Obstructive Lung Disease (GOLD). Accordingly, those patients on spirometry have FEV1/FVC ratio less than 70%, regardless FEV1. [1,8] FEV1 regardless of ratio (FRR) was defined as FEV1 less than 80%, not taking into consideration the FEV1/FVC ratio. This has the potential to miss GOLD COPD stage I. [1] Preserved ratio impaired Spirometry (PRISM), also labeled by some authorities as GOLD unclassified smokers, have been defined as those patients who have clinical and radiological features similar to patients with COPD, but on spirometry their FEV1 is less than 80% predicted with a normal FEV1/FVC ratio. [6] Validity of a test is calculation of its sensitivity, Specificity, Positive Predictive Value (PPV) and negative predictive value (NPV). Quantitative CT scan(qct) was defined as CT scan used to measure the lung volumes in maximal inspiration(total lung capacity TLC) and full expiration(functional residual capacity FRC); using multi detector CT scan and reconstruction imaging techniques. [10] Current or former smokers with a smoking history of more than 10 pack years, who came to the ambulatory clinics of Fauji Foundation Hospital for evaluation of their symptoms, were included in the study. Patients between 40-80 years of age were incorporated. Patients with normal spirometry, radiological evidence of any parenchymal lung disease including tuberculosis and bronchiectasis, non-smokers, huqqa smokers and patients in exacerbation were excluded. Informed consent was taken. Demographic features including age and sex, and smoking history, patient symptoms, co-morbid diseases, body mass index were recorded. Dyspnea was measured by 6 minute walk test. Arterial oxygen saturation, chest x-ray were performed. Medical International Research (MIR) microlab III spirometer was used. Spirometry was performed at baseline and 10minutes after bronchodilator challenge using salbutamol nebulization. Patients FEV1, FVC and FEV1/FVC ratio were noted. All patients underwent a multi-detector high resolution CT chest (HRCT), to measure the total lung capacity, taken as the gold standard. [11,12] Data was analyzed by calculating frequencies and percentages using SPSS version 20. Validity of FER, FRR was calculated by checking the sensitivity, specificity, positive and negative predictive values. PRISM was identified as a subgroup. RESULTS The mean age of patients was 63.41 +10.28. Around 108(87.80%) of patients were male while 15(12.20%) were female. A predominant male pattern may be due to a selection bias due to mainly male gender inclined towards cigarette smoking in Pakistan. [13] The mean smoking history was about 35.78+ 20.40 pack years. Approximately 88(71.50%) patients had dyspnea as the only symptom while 35(28.50%) of patients also complaint of cough with sputum. Around 63(51.20%) of patients had no comorbid illness while hypertension, diabetes and ischemic heart disease were concurrent conditions in 34(27.60%), 13(10.60%) and 13(10.60%) of patients respectively. 4

Results of hyperinflation on CXR and Increased Total lung capacity (TLC) on HRCT chest were consistent (91.10%), with HRCT chest being taken as the gold standard. The demographic features of these patients are depicted in table 1. Table 1: Demographic features. Demographic Features Age Sex Male Female Smoking Symptoms Dyspnea only Cough with Sputum Comorbid illness None HT Diabetes IHD MMRC grades dyspnea Body mass index (BMI) Arterial saturation (SaO2) Six Minute walk test (6MWT) Hyperinflation on CXR Yes No Total Lung Capacity Increased Not Increased Results Mean 63.41 +10.28(SD) 108 (87.80 %) 15 (12.20 %) Mean 35.78+ 20.40 pack years 88(71.50%) 35(28.50%) 63(51.20%) 34(27.60%) 13(10.60%) 13(10.60%) I 2.40% II 58.50% III 31.70% IV 7.30% 22.81(+ 3.74SD) 96.48(+ 2.32SD) 417.15(+53.79 SD) 112(91.10%) 11 (8.9%) 112(91.10%) 11 (8.9%) The mean MMRC grade of dyspnea was 2.44(+0.67SD) and body mass index (BMI) was 22.81(+3.74SD). The mean distance travelled by the patients was 410(+53.79) meters. 112 patients out of 123 were confirmed as COPD cases on total lung capacity measurement. Spirometry pattern is illustrated in Figure 1 below: Figure 1: Sample Spirometry using Gold Defined Criteria for COPD. The two groups identified by our study were Gold Defined COPD as termed as Forced Expiratory Ratio (FER) group and PRISM group. Characteristics of these two groups are described in table 2. Table 2: Comparison of Means. Variable Comparison of Means GOLD Defined COPD Preserved Ratio Impaired group(fer) Spirometry group(prism) P value Age 64.64(+10.47) years 61.95(+9.961)years 0.15 Smoking status 37.94(+21.36) pack years 33.20( + 19.07) pack years 0.20 BMI 22( +3.99)kg/m2 22( +3.45)kg/m2 0.68 Saturation(SaO2) 96( + 2.73)% 96.59( +2.26)% 0.24 6MWT 413( +55.81)m 421( +51.43)m 0.42 It is evident from table 2, that the GOLD Defined COPD group and the PRISM group are comparable with no statistically significant difference in their mean age, smoking status, arterial blood gas values and the six minute walk test. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) using Gold defined COPD criteria (Forced expiratory ratio FER), identifying patients with preserved ratio impaired Spirometry is given in table 3: 5

Table 3: Validity of Forced Expiratory ratio (GOLD defined COPD). Subgroup (total 123) Gold defined COPD (FER) PRISM Parameter on Spirometry FEV1/FVC <70% FEV1/FVC >70% FEV1<80% TLC (actual COPD) a=60 (False +ive) b=6 (False -ive) c=52 (true -ive) d=5 Frequency & percentage n(%) Sensitivity a/a+c Specificity d/d+b PPV a/a+b NPV d/c+d 66(53.70%) 54.46% 45.45% 91.04% 8.9% 57(46.30%) As is clearly evident from table 3 that the sensitivity and specificity of GOLD defined COPD (Forced Expiratory ratio or FER) is modest (53.50% and 45.50%). It is also evident from this table that preserved ratio impaired Spirometry (PRISM) is an important subgroup identified by measuring the total lung capacity (57 or 46.3% of patients) and is likely to be missed, if FER criteria is only used. Table 4 describes in detail the validity of FEV1 regardless of ratio(frr) using Total lung capacity as the gold standard. Table 4: Validity of FEV1 regardless of ratio (FRR). Subgroup (total 123) FEV1 regardless of ratio (FRR) No COPD based on FRR Parameter on Spirometry FEV1 <80% FEV1>80% TLC (actual COPD) a=110 (False +ive) b=10 (False -ive) c=2 (true -ive) d=1 Frequency & percentage n (%) Sensitivity a/a+c Specificity d/d+b PPV a/a+b NPV d/c+d 120(97.6%) 98.21% 9.09% 91.66% 33.33% 3(2.4%) It is evident from the table 4, that FRR has got an improved sensitivity (98.2%) and positive predictive value (91.66%). However, the specificity remains low (9.09%). The sensitivity of FRR to diagnose COPD is much higher than that of FER, tool currently recommended by GOLD guidelines(14). Specificity is a problem, as is the case with FER. However, in population studies and COPD screening in the hospitals, FEV1 regardless of ratio (FRR) is sensitive enough to replace FEV1/FVC ratio (Forced expiratory ratio FER). DISCUSSION The results of this study demonstrate that the sensitivity of Gold defined COPD (FEV1/FVC ratio < 70%) also known as forced expiratory ratio (FER) is modest around 53.6%. Numerous studies show that if we rely only on FER criteria, many cases with clinical, radiological and pathological diagnosis of emphysema are likely to be missed. In the COPD Gene study, these missed cases were termed as GOLD unclassified smokers (GOLD-U) and their frequency was found to be 8-14%. [15] In a later article by the same investigators, a new term was coined for these patients; preserved ratio impaired Spirometry(PRISM) with a prevalence of 12.3%. [6] In the present study, the frequency of PRISM was quite high around 46.3%. The reasons may include a selection bias, hospital setting as compared to community, predominance of male patients, high frequency of patients with MMRC grade II and III dyspnea, racial differences and a higher BMI in our study population, features specifically portrayed for PRISM. Future randomized controlled trials are required. The present study also demonstrates the specificity of FER is also low (45.45%). This is an indication that those patients, who are labeled as COPD on Spirometry, may have a false positive result. It has also been demonstrated in a study by Hansen and colleagues who advocated use of the 5 th percentile rather than fixed FEV1/FVC ratio< 70%, a criteria for COPD diagnosis in the general population. [9] To overcome the problems with Forced expiratory ratio (FER; FEV1/FVC<70%), and to avoid the difficulties in calculating the 5 th percentile, the author has advocated use of FEV1 regardless of ratio(frr) for screening of COPD cases. The sensitivity of FRR in the present study was more than 90%; implicating its use in mass screening programs for COPD, in the communities and multiple health care centers of the world. Another advantage of FRR is incorporation of patients with preserved ratio impaired Spirometry (PRISM). As is evident from this study and numerous other studies, this important subgroup of patients with clinical and 6

pathologically similar disease are likely to be missed if older criteria of FER is used to diagnose COPD. [15,6] There are few limitations of this study. Recruitment of smokers suspected of having COPD was done in a hospital based setting. This needs to be further verified in community based studies. Another limitation was the use of CT scan to predict total lung capacity in our study. This was primarily done because of feasibility issues and non-availability of total body plethysmography or Helium Dilution techniques in our center. Studies however, has shown good correlation between total lung capacity(tlc) measured by quantitative CT scan(qct), as compared to traditional methods. [11,10] This study has many implications. If found sensitive enough in future randomized controlled trials, FRR is likely to replace FER criteria for diagnosis of COPD. It is cheap, readily available and likely to have a wider utility in ambulatory settings. It will also incorporate patients who were previously named as unclassified smokers or patients with preserved ratio impaired Spirometry. Studies are also required to link PRISM representing specific genotype or phenotype of COPD. Their cellular mechanisms and the predominant cellular types need to be explored. Whether this subtype requires a different treatment regimen or a combination of inhaled therapy needs further more well designed trials. CONCLUSIONS This study shows that GOLD defined COPD (Forced Expiratory Ratio) and Preserved ratio impaired spirometry (PRISM) are different spectrum of the same disease. Though the gold standard for COPD diagnosis is measurement of Total Lung capacity (TLC) by either Total body plethysmography or Quantitative CT (QCT), but this TLC evaluation is neither mandatory nor required in ambulatory hospital and population screening programs. Using FEV1 regardless of ratio (FRR) is a an easy and widely available parameter that can be useful in future hence may reduce the morbidity and mortality that can be a consequence of missing a diagnosis. REFERENCES 1. Johns DP, Walters JAE, Walters EH. Diagnosis and early detection of COPD using spirometry, 2014; i(11): 1557 69. 2. Drummond MB. HHS Public Access, 2016; 385(9979): 1778 88. 3. Soriano JB, Miravitlles M, García-río F, Muñoz L, Sánchez G, Sobradillo V, et al. Spirometricallydefined restrictive ventilatory defect: population variability and individual determinants, 2012; 21(2): 187 93. 4. Regan EA, Lynch DA, Curran-everett D, Curtis JL, Austin JHM, Grenier PA, et al. Clinical and Radiologic Disease in Smokers With Normal Spirometry, 2017; 80206(9): 1539 49. 5. Bhatt SP, Soler X, Wang X, Murray S, Anzueto AR, Terri H. Association between Functional Small Airway Disease and FEV 1 Decline in Chronic Obstructive Pulmonary Disease, 2016. 6. Wan ES, Castaldi PJ, Cho MH, Hokanson JE, Regan EA, Make BJ, et al. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene, 2014; 1 13. 7. Nonato L, Nascimento OA, Padilla RP, Valdivia G, Oca MM De, Ta C, et al. Occurrence of respiratory symptoms in persons with restrictive ventilatory impairment compared with persons with chronic obstructive pulmonary disease : The PLATINO study, 2015. 8. Vandevoorde J, Verbanck S, Schuermans D, Kartounian J, Vincken W. Obstructive and restrictive spirometric patterns: fixed cut-offs for FEV 1 /FEV 6 and FEV 6, 2006; 27(2): 378 83. 9. E HJ, Xing-guo S, Karlman W. Spirometric Criteria for Airway. Chest [Internet], 2007; 131(2): 349 55. Available from: http://dx.doi.org/10.1378/chest.06-1349. 10. Come CE, Diaz AA, Curran-everett D, Muralidhar N, Hersh CP, Zach JA, et al. Characterizing Functional Lung Heterogeneity in COPD Using Reference Equations for CT Scan-Measured Lobar Volumes, 2013; 143(6): 1607 17. 11. Chen H, Rc C, Yb G, Li W, Liu Q, Qs Z. Correlation of pulmonary function indexes determined by low- dose MDCT with spirometric pulmonary function tests in patients with chronic obstructive pulmonary disease, 2014; 202(4): 10501. 12. Hersh CP, Washko GR, San R, Estépar J, Lutz S, Friedman PJ, et al. Paired inspiratory-expiratory chest CT scans to assess for small airways disease in COPD Background, 2013 April. 13. Ahmad K, Jafary F, Jehan I, Hatcher J, Khan AQ, Chaturvedi N, et al. Cardiovascular Risk Prevalence and predictors of smoking in Pakistan : results of the National Health Survey of Pakistan, 2005. 14. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. NHLBI/WHO Workshop Summary Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary, 2001; 163: 1256 76. 15. Wan ES, Hokanson JE, Murphy JR, Regan EA, Make BJ, Lynch A, et al. Clinical and Radiographic Predictors of GOLD Unclassified Smokers in the COPDGene Study, 2011; 184(1): 57 63. 7